[Activation of neutrophil function by MDP-Lys(L 18)].
The study was carried out to confirm the effect of MDP-Lys (L 18) on the neutrophil number and function in the patients with lung cancer. The patients were enrolled only in case of leukopenia (equal or less than 3,000/mm3 after anticancer chemotherapy) and subcutaneously given 200 mcg of MDP-Lys (L 18) for 7 days. Mean leukocyte counts were found to be 3,900/mm3 and 5,500/mm3 one day and one week after MDP-Lys (L 18) treatment, respectively. The rate of "markedly effective" and "effective" was 53% (8/15). Chemiluminescence by zymosan showed a significant increase after MDP-Lys (L 18) treatment. However, no change of neutrophil function was observed in the tests of chemiluminescence by phorbol myristate acetate, superoxide (O2-) production, hydrogen peroxide (H2O2) production, chemotaxis, bacterial killing and opsonization. Transient fever was observed in 6 cases and eruption accompanied with one fever case. It was concluded that MDP-Lys (L 18) could prevent infection in cancer-bearing immunocompromised patients by increasing the neutrophil number and function.
Hirota
M
M
2nd Dept. of Internal Medicine, Nagasaki Univ.
Senju
R
R
Kadota
J
J
Hiratani
K
K
Komori
K
K
Kanda
T
T
Hara
K
K
Hayashi
K
K
Tsuji
Y
Y
Watanabe
K
K
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D000369:Aged, 80 and over; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007108:Immune Tolerance; D007958:Leukocyte Count / Q000187:drug effects; D007970:Leukopenia / Q000097:blood / Q000188:drug therapy / Q000276:immunology; D008163:Luminescent Measurements; D008175:Lung Neoplasms / Q000097:blood / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009504:Neutrophils / Q000187:drug effects / Q000276:immunology*
D000119:Acetylmuramyl-Alanyl-Isoglutamine; C036866:romurtide